• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

    10/24/22 8:30:00 AM ET
    $BLZE
    $GSIT
    $PEN
    Computer Software: Prepackaged Software
    Technology
    Semiconductors
    Technology
    Get the next $BLZE alert in real time by email

    SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors.

    Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care.

    "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairman Daniel Appleby. "Barbara and Surbhi's experience in guiding cutting-edge technology companies from startup to Nasdaq will be invaluable as we grow in the US and around the world."

    "Barbara and Surbhi both add tremendous value to our board of directors. I look forward to working with them and am confident that their deep industry expertise will be invaluable as we usher humankind into a new era of precision brain medicine," said Omniscient CEO Stephen Scheeler.

    Omniscient is the first company to develop technology to translate connectomic research for actionable use by clinicians and surgeons. It does so via its product, Quicktome, which is an FDA-cleared precision brain mapping platform that today allows neurosurgeons to visualize a patient's unique brain networks prior to critical surgery.

    About the new appointees

    Barbara Nelson is a C-level technology executive with over 15 years of General Management and Profit & Loss leadership, across markets including SaaS, IaaS, cybersecurity, data management, mobile and consumer electronics. She has led global P&Ls, twice as CEO, for companies ranging from VC funded startups to Fortune 500 leaders such as Quantum and Intel; most recently having led strategy for the $3 billion consumer business at Western Digital. Barbara also currently serves as independent director on the boards of GSI Technology (NASDAQ:GSIT) and Backblaze (NASDAQ:BLZE), a business she led through a successful IPO.

    Surbhi Sarna is the founder and former CEO of nVision Medical, which was acquired by Boston Scientific in 2018. She is currently at Y Combinator as Group Partner where she invests in and works closely with companies in the bio, healthcare, and tech spaces. Surbhi is an invited speaker at universities including Stanford and Harvard and has received numerous awards, including named on the Forbes "30 under 30" list in 2014, the Inc "Female Founders 100" list in 2019, Business Insider's "Top Pioneering Biotech VCs" list in 2022 and the Medical Device and Diagnostic Industry "Omed 30 Under 30 Innovator" list in 2016. She currently serves on boards for companies including Penumbra (NYSE:PEN) and Astia, an angel group and venture fund that invests in female entrepreneurs.

    About Omniscient Neurotechnology

    Omniscient Neurotechnology (o8t™) builds personalized brain maps to diagnose, treat and prevent health conditions. It operates on the core belief that a better understanding of an individual's brain will lead to better outcomes for billions of people. Omniscient is a pioneer in connectomics, the study of the brain's connections, and is poised to change the future of neuroscience. Already used by neurosurgeons to visualize the brain's pathways prior to a procedure, the company's technology ultimately aims to transform brain health and address conditions such as Alzheimer's disease and depression. Headquartered in Sydney, Australia with offices throughout the world, Omniscient's team consists of leaders in neurology, data science and big tech. To learn more, visit o8t.com.  

    Media Contact:

    Kyle Owens

    [email protected]

    +1 (908) 947-0500 x709



    Get the next $BLZE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BLZE
    $GSIT
    $PEN

    CompanyDatePrice TargetRatingAnalyst
    Backblaze Inc.
    $BLZE
    6/24/2025$7.00Mkt Outperform
    Citizens JMP
    Penumbra Inc.
    $PEN
    3/14/2025$320.00Buy
    BofA Securities
    Backblaze Inc.
    $BLZE
    3/11/2025$8.00Buy
    Needham
    Penumbra Inc.
    $PEN
    1/21/2025$305.00Buy
    UBS
    Penumbra Inc.
    $PEN
    12/17/2024$275.00Outperform
    Oppenheimer
    Penumbra Inc.
    $PEN
    12/11/2024$190.00 → $275.00Equal Weight → Overweight
    Wells Fargo
    Penumbra Inc.
    $PEN
    9/18/2024$238.00Buy
    Stifel
    Penumbra Inc.
    $PEN
    9/3/2024$263.00Outperform
    Leerink Partners
    More analyst ratings

    $BLZE
    $GSIT
    $PEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

      Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

      10/10/24 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Backblaze Deepens Sales Leadership Team

      SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Backblaze, Inc. (NASDAQ:BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, today announced that Dave Cotten and Teresa Dodson joined the company's sales leadership team. "Adding these seasoned, senior-level sales leaders reinforces our commitment to delivering open cloud solutions that allow our customers to do more with their data," said Jason Wakeam, Chief Revenue Officer at Backblaze. "Dave and Teresa bring sales experience and a strategic approach to deepen relationships and better serve our customers and partners." The news follows the recent appointment of Jason Wakeam as the compan

      9/12/24 9:00:25 AM ET
      $BLZE
      Computer Software: Prepackaged Software
      Technology
    • Backblaze Names Marc Suidan Chief Financial Officer

      SAN MATEO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Backblaze, Inc. (NASDAQ:BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, today announced Marc Suidan is joining the company as Chief Financial Officer (CFO), effective August 16, 2024. "I am excited to welcome Marc as our Chief Financial Officer," said Gleb Budman, Backblaze CEO and Chairperson of the Board. "He has deep knowledge and experience strategically guiding companies through financial growth. His expertise and leadership will be a valuable asset as we empower customers to move to an open cloud and to do more with their data." Suidan brings to Backblaze more than 20 years of exp

      8/8/24 4:05:04 PM ET
      $BLZE
      $BODI
      Computer Software: Prepackaged Software
      Technology
      Other Consumer Services
      Consumer Discretionary

    $BLZE
    $GSIT
    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

      ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. Event: Canaccord Genuity 45th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 12:30pm ET/9:30am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks followi

      7/30/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports Second Quarter 2025 Financial Results

      ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024.U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% compared to the same period a year ago.Income from operations of $40.8 mil

      7/29/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Backblaze Advances Key Enterprise Security Features in Latest Platform Update

      New AI-powered Anomaly Alerts, enterprise web console, and role-based access controls underscore commitment to data security and simplified management. Backblaze, Inc. (NASDAQ:BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, today announced a suite of powerful new security features to help customers prevent, detect, and mitigate security risks related to their data. These product enhancements add to Backblaze's existing robust foundational security capabilities, including SOC 2 certified architecture and physical security, server-side encryption for data at rest, cross-origin resource sharing (CORS) support, and key platform features like

      7/29/25 9:01:00 AM ET
      $BLZE
      Computer Software: Prepackaged Software
      Technology

    $BLZE
    $GSIT
    $PEN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Penumbra Inc.

      10-Q - Penumbra Inc (0001321732) (Filer)

      7/29/25 4:53:53 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Penumbra Inc (0001321732) (Filer)

      7/29/25 4:14:41 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by GSI Technology

      DEF 14A - GSI TECHNOLOGY INC (0001126741) (Filer)

      7/17/25 4:04:03 PM ET
      $GSIT
      Semiconductors
      Technology

    $BLZE
    $GSIT
    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Backblaze with a new price target

      Citizens JMP initiated coverage of Backblaze with a rating of Mkt Outperform and set a new price target of $7.00

      6/24/25 7:59:33 AM ET
      $BLZE
      Computer Software: Prepackaged Software
      Technology
    • BofA Securities initiated coverage on Penumbra with a new price target

      BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00

      3/14/25 7:46:38 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Needham initiated coverage on Backblaze with a new price target

      Needham initiated coverage of Backblaze with a rating of Buy and set a new price target of $8.00

      3/11/25 7:20:49 AM ET
      $BLZE
      Computer Software: Prepackaged Software
      Technology

    $BLZE
    $GSIT
    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Elsesser Adam exercised 27,976 shares at a strike of $30.00 and sold $3,765,574 worth of shares (16,150 units at $233.16), increasing direct ownership by 9% to 146,258 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      7/25/25 7:32:18 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • CEO and President Elsesser Adam exercised 27,976 shares at a strike of $30.00 and sold $3,896,344 worth of shares (15,985 units at $243.75), increasing direct ownership by 10% to 134,432 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      7/11/25 7:30:17 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • EVP, Gen. Counsel & Secretary Roberts Johanna sold $151,622 worth of shares (600 units at $252.70), decreasing direct ownership by 0.90% to 66,057 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      7/3/25 7:54:20 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $BLZE
    $GSIT
    $PEN
    Financials

    Live finance-specific insights

    See more
    • Penumbra, Inc. Reports Second Quarter 2025 Financial Results

      ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024.U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% compared to the same period a year ago.Income from operations of $40.8 mil

      7/29/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Backblaze to Announce Second Quarter 2025 Results on August 7, 2025

      Backblaze, Inc. (NASDAQ:BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, will report financial results for its second quarter ending June 30, 2025 on Thursday, August 7, 2025 before market open. Following the release of results, Backblaze will host a conference call and webcast at 5:00 a.m. PT (8:00 a.m. ET) on August 7, 2025 to discuss the results. Attend the webcast: https://events.q4inc.com/attendee/666498838 Register to listen by phone: https://registrations.events/direct/Q4I9661615 Phone registrants will receive dial-in information via email. An archive of the webcast will be available shortly after its completion on the Investo

      7/17/25 4:10:00 PM ET
      $BLZE
      Computer Software: Prepackaged Software
      Technology
    • GSI Technology to Announce Fiscal First Quarter 2026 Results on July 31, 2025

      SUNNYVALE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- GSI Technology, Inc. (NASDAQ:GSIT), developer of the Gemini ® Associative Processing Unit (APU) for AI and high-performance parallel computing (HPPC) and a leading provider of high-performance memory solutions for networking, telecommunications and military markets, will announce financial results for its fiscal first quarter 2026 ended June 30, 2025 after the market close on Thursday, July 31, 2025. Management will also conduct a conference call to review the Company's first quarter financial results and its current outlook for the second quarter of fiscal 2026 at 1:30 p.m. Pacific time (4:30 p.m. Eastern Time) on that same day. To par

      7/17/25 6:00:00 AM ET
      $GSIT
      Semiconductors
      Technology

    $BLZE
    $GSIT
    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/14/24 1:22:36 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/12/24 12:53:28 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Backblaze Inc. (Amendment)

      SC 13G/A - Backblaze, Inc. (0001462056) (Subject)

      2/14/24 6:23:57 PM ET
      $BLZE
      Computer Software: Prepackaged Software
      Technology